China biopharmaceutical: second generation highly selective P2X3 inhibitor approved clinical trial

IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives

In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow

Doubt Cast on Singapore’s Effort to Preserve Hawker Culture

A new initiative allowing certain foreigners to work as food stall assistants in Singapore’s hawker trade may face challenges in attracting applicants due to the physically demanding nature of the job and its relatively low wages, policy experts suggest.

Argentina's wave of SME closures continues, with a bleak recovery outlook

New Import Tax Regulations in Brazil: Cross-Border Shopping to Enjoy Tax Discounts from Au

EqualOcean reports that starting August 1, 2024, under Brazil's newly passed Law No. 914/2024, purchases over USD 50 on international cross-border shopping platforms that are part of the "Conforme Remessa" import tax compliance program will benefit from reduced import taxes.

CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM

There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?